Zhenghang Wang

机构：Peking University, Mongolian National University of Medical Sciences, Peking University Cancer Hospital, Inner Mongolia Medical University · ORCID：0009-0004-4166-576X

发表论文 88 篇 · 总被引 2876 次 · h-index 26

代表论文

• Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results (2024 · Nature Medicine · 被引 194)
• Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data (2024 · Signal Transduction and Targeted Therapy · 被引 102)
• Recent developments in immunotherapy for gastrointestinal tract cancers (2024 · Journal of Hematology & Oncology · 被引 99)
• A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial (2025 · Nature Medicine · 被引 19)
• Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer. (2024 · Journal of Clinical Oncology · 被引 18)
• Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers (2024 · Cancer Immunology Immunotherapy · 被引 16)